公开(公告)号：US09988372B2

公开(公告)日：2018-06-05

申请号：US15325521

申请日：2014-07-18

Applicant: GREEN CROSS CORPORATION ,  LEGOCHEM BIOSCIENCES,INC.

Inventor： Soongyu Choi ,  Jungsub Choi ,  So-Hyun Yoon ,  Yoo Hoon Kim ,  Jae Yeon Kim ,  Suk Ho Lee ,  Young Lag Cho ,  Ho Young Song ,  Dae Yon Lee ,  Sung Yoon Baek ,  Sang Eun Chae ,  Tae Kyo Park ,  Sung Ho Woo ,  Yong Zu Kim

IPC: C07D253/065 ,  C07D409/10 ,  C07D413/10 ,  A61K31/53 ,  C07D413/14

CPC classification number: C07D413/14 ,  A61K31/53 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  C07B2200/13 ,  C07D253/065 ,  C07D409/10

Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.

公开(公告)号：US09340521B2

公开(公告)日：2016-05-17

申请号：US13845466

申请日：2013-03-18

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Jae Eun Kim ,  Kwang-Seop Song ,  Suk Ho Lee ,  Kisoo Park ,  Hee Jeong Seo ,  Min Ju Kim ,  Eun-Jung Park ,  So Ok Park ,  Younggyu Kong ,  Hyunku Kang ,  Ickhwan Son ,  Myung Eun Jung ,  Man-Young Cha ,  Hyun Jung Kim ,  Jun Sung Lee ,  Mi-Soon Kim ,  Min Woo Lee ,  Kinam Lee

IPC: C07D309/10 ,  C07D407/04 ,  C07D409/04 ,  C07D409/14

CPC classification number: C07D309/10 ,  C07D407/04 ,  C07D409/04 ,  C07D409/14

Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.

Abstract translation: 本发明涉及通过使用式I化合物或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其盐 其前药：其中环A，环B，X和Y具有与说明书中定义相同的含义。

公开(公告)号：US09371303B2

公开(公告)日：2016-06-21

申请号：US14593071

申请日：2015-01-09

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu Choi ,  Kwang-Seop Song ,  Suk Ho Lee ,  Min Ju Kim ,  Hee Jeong Seo ,  Eun-Jung Park ,  Younggyu Kong ,  So Ok Park ,  Hyunku Kang ,  Myung Eun Jung ,  Kinam Lee ,  Hyun Jung Kim ,  Jun Sung Lee ,  Min Woo Lee ,  Mi-Soon Kim ,  Dong Ho Hong ,  Misuk Kang

IPC: A61K31/351 ,  C07D407/04 ,  C07D309/10 ,  C07D405/10 ,  C07D407/10 ,  C07D407/14 ,  C07D409/04 ,  C07D409/10 ,  C07D411/10 ,  C07D413/04 ,  C07D405/14 ,  C07D413/10 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14

CPC classification number: C07D309/10 ,  C07D405/10 ,  C07D405/14 ,  C07D407/04 ,  C07D407/10 ,  C07D407/14 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D411/10 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14

Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.